barttin CLCNK type accessory subunit betaGenealiases: BART · DFNB73
Q-omics provides the consensus-scored BSND profile across patient tissues and cancer cell-line models. BSND expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BSND is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, BSND RNA expression shows 11,486 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where BSND shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BSND — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BSND survival associations across molecular data types. BSND RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BSND RNA expression–survival associations across cancer types. High BSND expression shows unfavorable associations in LIHC, KIRP, LGG, SKCM, CHOL and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BSND RNA expression.
This table summarizes BSND tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BSND. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BSND shows lower tumor expression in KIRC, KIRP, HNSC and PRAD and higher tumor expression in LIHC and KICH. The KIRC box plot shows higher BSND RNA expression in normal versus tumor tissue (log2 FC = −5.146, t-test p < 0.001).
This table shows molecular features associated with BSND in patient tissues and cancer cell lines. In patient samples, BSND shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BSND RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
